Currently, the only approved treatments for acute ischemic stroke (tissue plasminogen activator and embolectomy) must be administered or performed in the early post-stroke period, which, unfortunately accounts for only 10% of all stroke patients as the rest do not reach a hospital early enough to receive such interventions (2–4). This evidence concerns the gene PLAT and stroke disorder.